Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Market landscape • Market overview • Five forces analysis PART 06: Pipeline landscape PART 07: Market segmentation by therapy • Immunoglobulin therapy • Antibiotics • Others PART 08: Geographical segmentation • PIDDs treatment market in Americas • PIDDs treatment market in EMEA • PIDDs treatment market in APAC PART 09: Decision framework PART 10: Drivers and challenges • Market drivers • Market challenges PART 11: Market trends • Shift of manufacturing facilities to low-cost regions • Financial aid to plasma donors PART 12: Vendor landscape PART 13: Key vendor analysis • CSL Behring • Grifols • Pfizer • Shire • Other prominent vendors PART 14: Appendix • List of abbreviations List of Exhibits  Exhibit 01: Features of PIDDs Exhibit 02: Signs and symptoms of PI Exhibit 03: PIDDs classification based on affected immune system Exhibit 04: Diagnosis and treatment of PI Exhibit 05: Global PIDDs treatment market 2016-2021 ($ millions) Exhibit 06: Opportunity analysis of global PIDDs treatment market Exhibit 07: Five forces analysis Exhibit 08: Pipeline analysis of vendors in global PIDDs treatment market Exhibit 09: Key clinical trials Exhibit 10: Market segmentation by therapy Exhibit 11: Global PIDDs treatment market by immunoglobulin therapy 2016-2021 ($ millions) Exhibit 12: Global PIDDs treatment market by antibiotics 2016-2021 ($ millions) Exhibit 13: Antibiotic prophylaxis regimens in several PIDDs Exhibit 14: Global PIDDs treatment market by others 2016-2021 ($ millions) Exhibit 15: Segmentation of global PIDDs treatment market by geography 2016 and 2021 Exhibit 16: Global PIDDs treatment market revenue by geography 2016-2021 ($ millions) Exhibit 17: Market scenario in Americas Exhibit 18: PIDDs treatment market in Americas 2016-2021 ($ millions) Exhibit 19: Market scenario in EMEA Exhibit 20: PIDDs treatment market in EMEA 2016-2021 ($ millions) Exhibit 21: Market scenario in APAC Exhibit 22: PIDDs treatment market in APAC 2016-2021 ($ millions) Exhibit 23: Fractionation capacities of key vendors Exhibit 24: Various side effects associated with immunoglobulin therapy Exhibit 25: Factors contributing to overall cost of production for IVIG Exhibit 26: Detailed information regarding processes required for TGA approval Exhibit 27: Fractionating capacities globally in 2007 and 2012 Exhibit 28: Competitive structure analysis of global PIDDs treatment market 2016 Exhibit 29: Competitive factors of global PIDDs treatment market Exhibit 30: Market penetration of various PIDDs treatment manufacturers globally 2016 Exhibit 31: Strategic success factors of companies in global PIDDs treatment market Exhibit 32: CSL Behring: Key highlights Exhibit 33: CSL Behring: Strength assessment Exhibit 34: CSL Behring: Strategy assessment Exhibit 35: CSL Behring: Opportunity assessment Exhibit 36: Grifols: Key highlights Exhibit 37: Grifols: Strength assessment Exhibit 38: Grifols: Strategy assessment Exhibit 39: Grifols: Opportunity assessment Exhibit 40: Pfizer: Key highlights Exhibit 41: Pfizer: Strength assessment Exhibit 42: Pfizer: Strategy assessment Exhibit 43: Pfizer: Opportunity assessment Exhibit 44: Shire: Key highlights Exhibit 45: Shire: Strength assessment Exhibit 46: Shire: Strategy assessment Exhibit 47: Shire: Opportunity assessment

CSL Behring, Grifols, Pfizer, Shire, Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Biocon, Bristol-Myers Squibb, BDI Pharma, Bharat Serums and Vaccines, Eli Lilly, GlaxoSmithKline, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Lupin Pharmaceuticals, Mylan, Novartis, Octapharma, Sanofi, Sanquin, Takeda Pharmaceutical Company, Valneva, and Wockhardt.